Drug Topics November 7, 2022
Miranda Hester

Tackling Medicare Part D drug costs takes more than just capping costs.

The current cost sharing structure of Medicare Part D leaves many cancer patients feeling an economic pinch. Most beneficiaries have no limit on out-of-pocket costs and those costs are often calculated as a percentage of the list price instead of fixed copays. A recent editorial published in JAMA Oncology1 addressed the concerns.

With new cancer treatments having out-of-pocket costs of more than $10,000 per year, per drug, costs can quickly add up. A subsidy program exists for low-income Medicare patients, but only around 25% of beneficiaries qualified for this assistance in 2021. By comparison, other programs such as the Affordable Care Act and Tricare have much lower caps...

Today's Sponsors


Today's Sponsor

Health Edge

Topics: Biotechnology, Insurance, Medicare, Pharma, Pharma / Biotech
Top Healthcare Industry Facts for 2023
Inflation Reduction Act Could Cut Medicare Drug Spending by 5%, Study Suggests
States with the largest dual-eligible populations
Smoothing Medicare Part D Out-Of-Pocket Costs Under The Inflation Reduction Act
CMS proposes universal quality measures across all programs

Share This Article